Väinö Lithovius1, Jonna Saarimäki-Vire2, Diego Balboa2,3, Hazem Ibrahim2, Hossam Montaser2, Tom Barsby2, Timo Otonkoski4. 1. Stem Cells and Metabolism Research Program in the Faculty of Medicine of the University of Helsinki, Helsinki, Finland. vaino.lithovius@helsinki.fi. 2. Stem Cells and Metabolism Research Program in the Faculty of Medicine of the University of Helsinki, Helsinki, Finland. 3. Bioinformatics and Genomics Program, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. 4. Stem Cells and Metabolism Research Program in the Faculty of Medicine of the University of Helsinki, Helsinki, Finland. timo.otonkoski@helsinki.fi.
Abstract
AIMS/HYPOTHESIS: Congenital hyperinsulinism caused by mutations in the KATP-channel-encoding genes (KATPHI) is a potentially life-threatening disorder of the pancreatic beta cells. No optimal medical treatment is available for patients with diazoxide-unresponsive diffuse KATPHI. Therefore, we aimed to create a model of KATPHI using patient induced pluripotent stem cell (iPSC)-derived islets. METHODS: We derived iPSCs from a patient carrying a homozygous ABCC8V187D mutation, which inactivates the sulfonylurea receptor 1 (SUR1) subunit of the KATP-channel. CRISPR-Cas9 mutation-corrected iPSCs were used as controls. Both were differentiated to stem cell-derived islet-like clusters (SC-islets) and implanted into NOD-SCID gamma mice. RESULTS: SUR1-mutant and -corrected iPSC lines both differentiated towards the endocrine lineage, but SUR1-mutant stem cells generated 32% more beta-like cells (SC-beta cells) (64.6% vs 49.0%, p = 0.02) and 26% fewer alpha-like cells (16.1% vs 21.8% p = 0.01). SUR1-mutant SC-beta cells were 61% more proliferative (1.23% vs 0.76%, p = 0.006), and this phenotype could be induced in SUR1-corrected cells with pharmacological KATP-channel inactivation. The SUR1-mutant SC-islets secreted 3.2-fold more insulin in low glucose conditions (0.0174% vs 0.0054%/min, p = 0.0021) and did not respond to KATP-channel-acting drugs in vitro. Mice carrying grafts of SUR1-mutant SC-islets presented with 38% lower fasting blood glucose (4.8 vs 7.7 mmol/l, p = 0.009) and their grafts failed to efficiently shut down insulin secretion during induced hypoglycaemia. Explanted SUR1-mutant grafts displayed an increase in SC-beta cell proportion and SC-beta cell nucleomegaly, which was independent of proliferation. CONCLUSIONS/ INTERPRETATION: We have created a model recapitulating the known pathophysiology of KATPHI both in vitro and in vivo. We have also identified a novel role for KATP-channel activity during human islet development. This model will enable further studies for the improved understanding and clinical management of KATPHI without the need for primary patient tissue.
AIMS/HYPOTHESIS: Congenital hyperinsulinism caused by mutations in the KATP-channel-encoding genes (KATPHI) is a potentially life-threatening disorder of the pancreatic beta cells. No optimal medical treatment is available for patients with diazoxide-unresponsive diffuse KATPHI. Therefore, we aimed to create a model of KATPHI using patient induced pluripotent stem cell (iPSC)-derived islets. METHODS: We derived iPSCs from a patient carrying a homozygous ABCC8V187D mutation, which inactivates the sulfonylurea receptor 1 (SUR1) subunit of the KATP-channel. CRISPR-Cas9 mutation-corrected iPSCs were used as controls. Both were differentiated to stem cell-derived islet-like clusters (SC-islets) and implanted into NOD-SCID gamma mice. RESULTS: SUR1-mutant and -corrected iPSC lines both differentiated towards the endocrine lineage, but SUR1-mutant stem cells generated 32% more beta-like cells (SC-beta cells) (64.6% vs 49.0%, p = 0.02) and 26% fewer alpha-like cells (16.1% vs 21.8% p = 0.01). SUR1-mutant SC-beta cells were 61% more proliferative (1.23% vs 0.76%, p = 0.006), and this phenotype could be induced in SUR1-corrected cells with pharmacological KATP-channel inactivation. The SUR1-mutant SC-islets secreted 3.2-fold more insulin in low glucose conditions (0.0174% vs 0.0054%/min, p = 0.0021) and did not respond to KATP-channel-acting drugs in vitro. Mice carrying grafts of SUR1-mutant SC-islets presented with 38% lower fasting blood glucose (4.8 vs 7.7 mmol/l, p = 0.009) and their grafts failed to efficiently shut down insulin secretion during induced hypoglycaemia. Explanted SUR1-mutant grafts displayed an increase in SC-beta cell proportion and SC-beta cell nucleomegaly, which was independent of proliferation. CONCLUSIONS/ INTERPRETATION: We have created a model recapitulating the known pathophysiology of KATPHI both in vitro and in vivo. We have also identified a novel role for KATP-channel activity during human islet development. This model will enable further studies for the improved understanding and clinical management of KATPHI without the need for primary patient tissue.
Authors: T Otonkoski; C Ammälä; H Huopio; G J Cote; J Chapman; K Cosgrove; R Ashfield; E Huang; J Komulainen; F M Ashcroft; M J Dunne; J Kere; P M Thomas Journal: Diabetes Date: 1999-02 Impact factor: 9.461
Authors: P M Thomas; G J Cote; N Wohllk; B Haddad; P M Mathew; W Rabl; L Aguilar-Bryan; R F Gagel; J Bryan Journal: Science Date: 1995-04-21 Impact factor: 47.728
Authors: N Scott Adzick; Diva D De Leon; Lisa J States; Katherine Lord; Tricia R Bhatti; Susan A Becker; Charles A Stanley Journal: J Pediatr Surg Date: 2018-10-05 Impact factor: 2.545
Authors: Ritika R Kapoor; Sarah E Flanagan; Ved Bhushan Arya; Julian P Shield; Sian Ellard; Khalid Hussain Journal: Eur J Endocrinol Date: 2013-03-15 Impact factor: 6.664
Authors: Diego Balboa; Tom Barsby; Väinö Lithovius; Jonna Saarimäki-Vire; Muhmmad Omar-Hmeadi; Oleg Dyachok; Hossam Montaser; Per-Eric Lund; Mingyu Yang; Hazem Ibrahim; Anna Näätänen; Vikash Chandra; Helena Vihinen; Eija Jokitalo; Jouni Kvist; Jarkko Ustinov; Anni I Nieminen; Emilia Kuuluvainen; Ville Hietakangas; Pekka Katajisto; Joey Lau; Per-Ola Carlsson; Sebastian Barg; Anders Tengholm; Timo Otonkoski Journal: Nat Biotechnol Date: 2022-03-03 Impact factor: 68.164
Authors: Irene Miguel-Escalada; Miguel Ángel Maestro; Diego Balboa; Anamaria Elek; Aina Bernal; Edgar Bernardo; Vanessa Grau; Javier García-Hurtado; Arnau Sebé-Pedrós; Jorge Ferrer Journal: Dev Cell Date: 2022-08-22 Impact factor: 13.417